[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![ABBONews Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::102177005.png) ABBO News [@ABBONews](/creator/twitter/ABBONews) on x 13.9K followers
Created: 2025-07-17 12:30:47 UTC

🚨Analyst Action: Needham has reaffirmed its "Buy" rating and $XX price target on Sarepta Therapeutics $SRPT following the company’s strategic reorganization announcement.

Sarepta plans to reduce its workforce by approximately XX% as part of broader restructuring efforts.

The company also reported preliminary second-quarter 2025 results, with Elevidys sales reaching approximately $XXX million, marking a XX% decline QoQ.

Management expressed confidence in meeting its 2027 convertible note obligations, which Needham noted as easing a significant overhang on the stock.

![](https://pbs.twimg.com/media/GwD0Jf1WcAAYgEi.jpg)

XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1945823493070987310/c:line.svg)

**Related Topics**
[chapter 11](/topic/chapter-11)
[$srpt](/topic/$srpt)
[sarepta therapeutics](/topic/sarepta-therapeutics)
[sarepta therapeutics inc](/topic/sarepta-therapeutics-inc)
[stocks healthcare](/topic/stocks-healthcare)

[Post Link](https://x.com/ABBONews/status/1945823493070987310)